Global X Genomics & Biotechnology ETFGlobal X Genomics & Biotechnology ETFGlobal X Genomics & Biotechnology ETF

Global X Genomics & Biotechnology ETF

No trades
See on Supercharts

Key stats


Assets under management (AUM)
‪41.28 M‬USD
Fund flows (1Y)
‪−37.58 M‬USD
Dividend yield (indicated)
Discount/Premium to NAV
Shares outstanding
‪5.28 M‬
Expense ratio
0.50%

About Global X Genomics & Biotechnology ETF


Issuer
Mirae Asset Global Investments Co., Ltd.
Brand
Global X
Inception date
Apr 5, 2019
Structure
Open-Ended Fund
Index tracked
Solactive Genomics Index
Replication method
Physical
Management style
Passive
Dividend treatment
Distributes
Distribution tax treatment
Qualified dividends
Income tax type
Capital Gains
Max ST capital gains rate
39.60%
Max LT capital gains rate
20.00%
Primary advisor
Global X Management Co. LLC
Distributor
SEI Investments Distribution Co.
GNOM is Global X’s take on biotech, with more of an emphasis on genomics specifically. The fund fleshes out its description of this sector by including companies that derive more than 50% of their revenues from the following five business activities: (i) gene editing, (ii) genomic sequencing, (iii) development and testing of genetic medicine/therapies, (iv) computational genomics and genetic diagnostics, and/or (v) biotechnology. The fund uses a proprietary natural language processing algorithm to identify and rank eligible firms based on public documents, such as filings and disclosures. Holdings may span the market-cap spectrum and come from across the globe, including some emerging markets. The market-cap-weighted index is reconstituted and rebalanced semi-annually.

Classification


Asset Class
Equity
Category
Sector
Focus
Theme
Niche
Genomic advancements
Strategy
Vanilla
Geography
Global
Weighting scheme
Market cap
Selection criteria
Market cap
What's in the fund
Exposure type
StocksBonds, Cash & Other
Health Technology
Stock breakdown by region
80%16%3%
Top 10 holdings
Summarizing what the indicators are suggesting.
Oscillators
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Oscillators
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Moving Averages
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Moving Averages
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.

Broaden your horizons with more funds linked to GNOM via country, focus, and more.

Frequently Asked Questions


An exchange-traded fund (ETF) is a collection of assets (stocks, bonds, commodities, etc.) that track an underlying index and can be bought on an exchange like individual stocks.
GNOM trades at 7.77 USD today, its price has fallen −0.64% in the past 24 hours. Track more dynamics on GNOM price chart.
GNOM net asset value is 7.77 today — it's fallen 5.24% over the past month. NAV represents the total value of the fund's assets less liabilities and serves as a gauge of the fund's performance.
GNOM assets under management is ‪41.28 M‬ USD. AUM is an important metric as it reflects the fund's size and can serve as a gauge of how successful the fund is in attracting investors, which, in its turn, can influence decision-making.
GNOM price has fallen by −3.00% over the last month, and its yearly performance shows a −23.37% decrease. See more dynamics on GNOM price chart.
NAV returns, another gauge of an ETF dynamics, have fallen by −5.24% over the last month, showed a −15.82% decrease in three-month performance and has decreased by −23.30% in a year.
GNOM fund flows account for ‪−37.58 M‬ USD (1 year). Many traders use this metric to get insight into investors' sentiment and evaluate whether it's time to buy or sell the fund.
Since ETFs work like an individual stock, they can be bought and sold on exchanges (e.g. NASDAQ, NYSE, EURONEXT). As it happens with stocks, you need to select a brokerage to access trading. Explore our list of available brokers to find the one to help execute your strategies. Don't forget to do your research before getting to trading. Explore ETFs metrics in our ETF screener to find a reliable opportunity.
GNOM invests in stocks. See more details in our Analysis section.
GNOM expense ratio is 0.50%. It's an important metric for helping traders understand the fund's operating costs relative to assets and how expensive it would be to hold the fund.
No, GNOM isn't leveraged, meaning it doesn't use borrowings or financial derivatives to magnify the performance of the underlying assets or index it follows.
In some ways, ETFs are safe investments, but in a broader sense, they're not safer than any other asset, so it's crucial to analyze a fund before investing. But if your research gives a vague answer, you can always refer to technical analysis.
Today, GNOM technical analysis shows the sell rating and its 1-week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1-month rating GNOM shows the sell signal. See more of GNOM technicals for a more comprehensive analysis.
GNOM shares are issued by Mirae Asset Global Investments Co., Ltd.
GNOM follows the Solactive Genomics Index. ETFs usually track some benchmark seeking to replicate its performance and guide asset selection and objectives.
The fund started trading on Apr 5, 2019.
The fund's management style is passive, meaning it's aiming to replicate the performance of the underlying index by holding assets in the same proportions as the index. The goal is to match the index's returns.